SCYNEXIS (NASDAQ: SCYX) is one of 103 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare SCYNEXIS to related companies based on the strength of its valuation, institutional ownership, risk, dividends, analyst recommendations, earnings and profitability.
Volatility and Risk
SCYNEXIS has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, SCYNEXIS’s peers have a beta of 36.14, suggesting that their average share price is 3,514% more volatile than the S&P 500.
This table compares SCYNEXIS and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SCYNEXIS Competitors||$8.17 billion||$1.09 billion||177.66|
SCYNEXIS’s peers have higher revenue and earnings than SCYNEXIS.
This table compares SCYNEXIS and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for SCYNEXIS and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SCYNEXIS currently has a consensus target price of $9.50, suggesting a potential upside of 311.26%. As a group, “Pharmaceuticals” companies have a potential upside of 18.43%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, equities research analysts plainly believe SCYNEXIS is more favorable than its peers.
Institutional and Insider Ownership
30.9% of SCYNEXIS shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are held by institutional investors. 4.0% of SCYNEXIS shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
SCYNEXIS peers beat SCYNEXIS on 9 of the 12 factors compared.
SCYNEXIS Company Profile
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
What are top analysts saying about SCYNEXIS? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SCYNEXIS and related companies.